Skip to contentE
Endovia Health Sciences, Inc.
E
EDVAEndovia Health Sciences, Inc. Q2 2025 · 10-Q
Revenue—
Net Income-$8.49M-$8.49MN/M vs Q2 2024 EPS Diluted-$17.88-$17.88N/M vs Q2 2024 Gross Profitderived-$32,146N/M Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endovia Health Sciences, Inc. · CIK 1553788 · Engraved from SEC EDGAR
Operating Cash Flowderived-$551,123N/M ended Jun 30, 2025 · filed Aug 14, 2025 · 45 d after period end